Revenue from operations grew 19.87% year on year (YoY) to Rs 5,237 crore in the quarter ended 30 September 2024. Profit before tax was at Rs 1,270.9 crore in Q2 FY25, up 26.18% from Rs 1,007.2 crore reported in Q2 FY24. EBITDA stood at Rs 1,461.4 crore, registering the growth of 27.51% as compared to Rs 1,146.1 crore posted in same quarter last year. EBITDA margin improved to 27.9% in Q2 FY25 as against 26.2% in Q2 FY24. Research & Development (R&D) investments for the quarter stood at Rs 480 crore in Q2 FY25, up 50.23% from Rs 319.5 crore in Q2 FY24, which represented 9.2% of revenues. Additionally, organic capital expenditures (Capex) rose 39.54% YoY to Rs 301.7 in Q2 FY25. In terms of segment revenue, Formulations business grew by 9% YoY to Rs 1,456.9 crore. The business accounted for 28% of consolidated revenues. Branded business grew faster than the market with 10% YoY growth. Outpaced the market growth both in chronic and acute segments. Revenue from US Formulation business stood at Rs 2,416.8 crore in Q2 FY25, up 30% YoY. The business accounted for 47% of consolidated revenues. In constant currency terms, the business registered revenues of $ 288 million. Consumer Wellness generated Rs 487.5 crore in revenue, registering a 12% YoY growth. This segment accounted for 10% of the company's consolidated revenues. The growth was primarily led by 8.4% volume growth. Revenue from International Markets formulations business stood at Rs 538.9 crore, up 20% YoY. The business accounted for 11% of consolidated revenues. The business continued to deliver healthy growth with all major markets contributing to the growth during the quarter. The API business generated revenue of Rs 119.4 crore, down 15% YoY. This segment contributed 2% to the company's consolidated revenues. The Alliances and Others segment generated revenue of Rs 94.1 crore, registering a YoY growth of 178%. This segment contributed 2% to the company's consolidated revenues. During the quarter, the company has Received Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for the inspection of transdermal formulations facility located in Ahmedabad SEZ. Sharvil Patel, managing director, Zydus Lifesciences, said, Sustained growth momentum across our businesses along with enhanced profitability drove our strong Q2 performance. Execution success of our differentiated pipeline in the US and outperformance of our India Geography business were particularly noteworthy. With a focus on quality excellence, we will continue to align our processes and strengthen compliance. We are on course to achieve our growth aspirations for FY25 and are committed to investing in sustainable growth initiatives and innovative solutions, keeping patient centricity at the core. Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The scrip declined 2.02% to Rs 949 on the BSE. Powered by Capital Market - Live

Net profit of Zydus Lifesciences rose 13.80% to Rs 911.20 crore in the quarter ended September 2024 as against Rs 800.70 crore during the previous quarter ended September 2023. Sales rose 20.08% to Rs 5113.60 crore in the quarter ended September 2024 as against Rs 4258.60 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales5113.604258.60 20 OPM %28.5826.91 - PBDT1504.501191.40 26 PBT1270.901007.20 26 NP911.20800.70 14 Powered by Capital Market - Live

Zydus Lifesciences will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live

Fludrocortisone Acetate tablets are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome. The drug will be produced at the Group's manufacturing site at Moraiya, Ahmedabad. According to IQVIA MAT July 2024, Fludrocortisone acetate tablets generated annual sales of $19.9 million in the United States. The group now has 400 approvals and has so far filed over 465 ANDAs since the commencement of the filing process in FY 2003-04. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The pharma company's consolidated net profit surged 30.64% to Rs 1,419.9 crore on 20.77% increase in revenue from operations to Rs 6,207.5 crore in Q1 FY25 over Q1 FY24. Shares of Zydus Lifesciences fell 0.19% to Rs 1,019 on the BSE. Powered by Capital Market - Live

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Fludrocortisone Acetate Tablets USP, 0.1 mg (USRLD: Florinef Tablets, 0.1 mg). Fludrocortisone acetate tablets are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome. Fludrocortisone acetate tablets will be produced at the Group's manufacturing site at Moraiya, Ahmedabad. Fludrocortisone acetate tablets had annual sales of USD 19.9 mn in the United States (IQVIA MAT July 2024).Powered by Capital Market - Live

Zydus Lifesciences has formalized the Memorandum of Agreement (MoA) with Indian Council of Medical Research (ICMR) to initiate Phase 2 clinical trials of Desidustat in patients with Sickle Cell Disease. This Phase IIa, double blind, randomized, placebo controlled, parallel, multi-centre, proof-of-concept study, co-funded and co-monitored by INTENT, Indian National Clinical Trial and Education Network, Clinical Studies and Trial Unit, Division of Development Research, ICMR, will evaluate the efficacy and safety of Desidustat oral tablet for treatment of sickle cell disease. Proportion of patients with Hb response (defined as '' 1 g/dL increase in Hb from baseline) compared to placebo will be measured at week 4 and week 8 as the primary end-point. The trial will also evaluate Key Secondary Endpoints including Mean change in haemoglobin, proportion of patients requiring blood transfusions, proportion of patients experiencing vaso-occlusive crisis and mean change in percentage of HbSS. Pankaj Patel, Chairman of Zydus Lifesciences, mentioned that ''Public-private partnerships in the healthcare sector is essential to deliver novel drug to achieve the goals of the National Sickle Cell Anaemia Elimination Mission. The initiation of this study reaffirms hope for the 20 million Sickle Cell affected patients in the country for a high potential novel treatment.'' Powered by Capital Market - Live

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg (USRLD: Invega Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg). Paliperidone extended-release tablets are indicated for the acute and maintenance treatment of schizophrenia, acute treatment of schizoaffective disorder as monotherapy and acute treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants. Paliperidone extended-release tablets will be produced at the Group's manufacturing site at SEZ, Ahmedabad. Paliperidone extended-release tablets had annual sales of USD XXX 47.1 in the United States (IQVIA MAT July 2024). Powered by Capital Market - Live

Paliperidone extended-release tablets are indicated for the acute and maintenance treatment of schizophrenia, acute treatment of schizoaffective disorder as monotherapy and acute treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants. The drug will be manufactured at the group's formulation manufacturing facility in SEZ, Ahmedabad. The group now has 400 approvals and has so far filed over 465* ANDAs since the commencement of the filing process in FY 2003-04. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The pharma company's consolidated net profit surged 30.64% to Rs 1,419.9 crore in Q1 FY25 as compared to Rs 1,086.9 crore posted in Q1 FY24. Revenue from operations jumped 20.77% year on year (YoY) to Rs 6,207.5 crore in the quarter ended 30 June 2024. Shares of Zydus Lifesciences fell 0.86% to Rs 1056 on the BSE.Powered by Capital Market - Live

Zydus Lifesciences has received the EIR report from the USFDA for the inspection conducted at its transdermal patch manufacturing facility located at Pharmez, Ahmedabad. This facility underwent an inspection from 15 to 19 July 2024 and has been classified as Voluntary Action Indicated (VAI). Powered by Capital Market - Live

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Enzalutamide Capsules, 40 mg (USRLD: Xtandi' Capsules, 40 mg). Enzalutamide capsules are androgen receptor inhibitors indicated for the treatment of patients with metastatic castration-resistant prostate cancer. Enzalutamide Capsules will be produced at the Group's manufacturing site at Moraiya, Ahmedabad. Enzalutamide capsules, 40 mg had annual sales of USD 869.4 mn in the United States (IQVIA MAT July 2024). Powered by Capital Market - Live